| Patent application number | Description | Published |
|---|
| 20080280919 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS - Disclosed are methods for use of compounds of formula (I) in combination with other active substances in the treatment of CNS disorders such as depression or anxiety. | 11-13-2008 |
| 20090042897 | Chemical Compounds - The present invention relates to novel compounds or a pharmaceutically acceptable salt or solvate thereof, selected from a group consisting of:
| 02-12-2009 |
| 20090203705 | Spiro Compounds As NPY Y5 Receptor Antagonists - The present invention relates to novel compounds of formula (I), or a pharmaceutically acceptable salt thereof, | 08-13-2009 |
| 20090312546 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS - Disclosed are methods for the preparation of compounds of formula (I): | 12-17-2009 |
| 20100197699 | I-OXA-3-Azaspiro (4.5) Decan-2-One And 1-OXA-3, 8-Diazaspiro (4.5) Decan-2-One Derivatives For The Treatment of Eating Disorders - The present invention relates to novel compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, | 08-05-2010 |
| 20100204273 | Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors - Disclosed are methods for use of compounds of formula (I) in the treatment of CNS disorders such as dysthymia, schizophrenia, panic disorder, obsessive compulsive disorder, post-traumatic stress disorder, pain, and memory disorders: | 08-12-2010 |
| 20100216821 | Benzimidazoles With A Hetero Spiro-Decane Residue As NPY-Y5 Antagonists - The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salts, solvates, stereoisomers thereof, | 08-26-2010 |
| 20100286151 | 1-OXA-3-Azaspiro[4,5]Decan--2-One Derivatives For The Treatment Of Eating Disorders - The present invention relates to novel compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, | 11-11-2010 |
